Pyxis Oncology Inc
PYXS1.110USD
0.000
Close 12/26, 16:00（ET）Quotes delayed by 15 min
68.99MMarket Cap
LossP/E TTM
More Details of Pyxis Oncology Inc Company
Pyxis Oncology, Inc. is a clinical-stage company focused on developing therapeutics to target difficult-to-treat cancers. The Company is building therapeutics that hold the potential for mono and combination therapies. Its clinical program portfolio includes micvotobart pelidotin (MICVO), PYX-106, Sotigalimab (PYX-107), PYX-203, PYX-102, and APX601. The Company’s lead product candidate, MICVO, is an antibody-drug conjugate (ADC) that targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response. The Company’s ADC, MICVO, consists of human Immunoglobulin G1 (IgG1) and is site-specifically conjugated with a cleavable linker and a microtubule inhibitor (optimized auristatin) payload.
Pyxis Oncology Inc Info
Ticker SymbolPYXS
Company namePyxis Oncology Inc
IPO dateOct 08, 2021
CEOSullivan (Lara S)
Number of employees44
Security typeOrdinary Share
Fiscal year-endOct 08
Address321 Harrison Avenue
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02118
Phone16172219059
Websitehttps://pyxisoncology.com/
Ticker SymbolPYXS
IPO dateOct 08, 2021
CEOSullivan (Lara S)
Company Executives of Pyxis Oncology Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jitendra Wadhane
Mr. Jitendra Wadhane
Principal Financial Officer, Senior Vice President - Finance
Principal Financial Officer, Senior Vice President - Finance
393.42K
+50.20%
Mr. Darren S. Cline
Mr. Darren S. Cline
Independent Director
Independent Director
251.41K
+16.29%
Dr. Freda C. Lewis-Hall, M.D.
Dr. Freda C. Lewis-Hall, M.D.
Independent Director
Independent Director
241.41K
+17.08%
Mr. Thomas Civik
Mr. Thomas Civik
Independent Director
Independent Director
221.89K
--
Dr. Jakob Dupont, M.D.
Dr. Jakob Dupont, M.D.
Independent Director
Independent Director
38.74K
-75.40%
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
6.00K
--
Dr. Rachel W. Humphrey, M.D.
Dr. Rachel W. Humphrey, M.D.
Independent Director
Independent Director
--
--
Mr. John L. Flavin
Mr. John L. Flavin
Independent Chairman Of The Board
Independent Chairman Of The Board
--
--
Dr. Lara S. Sullivan, M.D.
Dr. Lara S. Sullivan, M.D.
Director, President, Chief Executive Officer and Chief Medical Officer
Director, President, Chief Executive Officer and Chief Medical Officer
--
--
Mr. Michael A. Metzger
Mr. Michael A. Metzger
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jitendra Wadhane
Mr. Jitendra Wadhane
Principal Financial Officer, Senior Vice President - Finance
Principal Financial Officer, Senior Vice President - Finance
393.42K
+50.20%
Mr. Darren S. Cline
Mr. Darren S. Cline
Independent Director
Independent Director
251.41K
+16.29%
Dr. Freda C. Lewis-Hall, M.D.
Dr. Freda C. Lewis-Hall, M.D.
Independent Director
Independent Director
241.41K
+17.08%
Mr. Thomas Civik
Mr. Thomas Civik
Independent Director
Independent Director
221.89K
--
Dr. Jakob Dupont, M.D.
Dr. Jakob Dupont, M.D.
Independent Director
Independent Director
38.74K
-75.40%
Mr. Santhosh Palani, Ph.D.
Mr. Santhosh Palani, Ph.D.
Independent Director
Independent Director
6.00K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Pfizer Inc
11.29%
GordonMD Global Investments LP
6.16%
Laurion Capital Management LP
5.82%
Bayer World Investments BV
4.40%
Tang Capital Management, LLC
4.02%
Other
68.30%
Shareholders
Shareholders
Proportion
Pfizer Inc
11.29%
GordonMD Global Investments LP
6.16%
Laurion Capital Management LP
5.82%
Bayer World Investments BV
4.40%
Tang Capital Management, LLC
4.02%
Other
68.30%
Shareholder Types
Shareholders
Proportion
Hedge Fund
16.50%
Corporation
15.70%
Investment Advisor
14.66%
Individual Investor
7.59%
Investment Advisor/Hedge Fund
2.82%
Research Firm
2.00%
Private Equity
1.89%
Venture Capital
0.80%
Endowment Fund
0.08%
Other
37.95%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
203
20.78M
33.38%
-18.55M
2025Q2
209
38.70M
62.47%
-13.38M
2025Q1
216
38.34M
62.12%
-14.52M
2024Q4
213
39.78M
66.90%
-17.18M
2024Q3
192
46.99M
81.54%
-6.22M
2024Q2
176
47.00M
84.53%
-2.80M
2024Q1
171
42.24M
77.42%
+2.97M
2023Q4
155
21.66M
52.75%
-11.58M
2023Q3
153
21.37M
52.33%
-11.59M
2023Q2
144
21.88M
56.33%
-9.87M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Pfizer Inc
7.03M
11.34%
--
--
Jun 30, 2025
GordonMD Global Investments LP
3.83M
6.18%
+3.83M
--
Jul 14, 2025
Laurion Capital Management LP
3.63M
5.85%
--
--
Jun 30, 2025
Bayer World Investments BV
2.74M
4.42%
--
--
Sep 30, 2024
Tang Capital Management, LLC
2.50M
4.03%
+1.40M
+127.27%
Jun 30, 2025
The Vanguard Group, Inc.
2.15M
3.47%
-287.33K
-11.79%
Jun 30, 2025
Sullivan (Lara S. M.D.)
1.87M
3.01%
-537.34K
-22.35%
Apr 21, 2025
Connealy (Pamela Ann)
1.20M
1.93%
+670.09K
+126.66%
Apr 21, 2025
Palo Alto Investors LP
1.04M
1.67%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0.03%
ProShares Ultra Nasdaq Biotechnology
0.02%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.01%
Tema Oncology ETF
0%
Avantis US Small Cap Value ETF
0%
Avantis US Small Cap Equity ETF
0%
Global X Russell 2000 ETF
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
View more
iShares Micro-Cap ETF
Proportion0.03%
ProShares Ultra Nasdaq Biotechnology
Proportion0.02%
Invesco Nasdaq Biotechnology ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.01%
Tema Oncology ETF
Proportion0%
Avantis US Small Cap Value ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Pyxis Oncology Inc?
The top five shareholders of Pyxis Oncology Inc are:
Pfizer Inc holds 7.03M shares, accounting for 11.34% of the total shares.
GordonMD Global Investments LP holds 3.83M shares, accounting for 6.18% of the total shares.
Laurion Capital Management LP holds 3.63M shares, accounting for 5.85% of the total shares.
Bayer World Investments BV holds 2.74M shares, accounting for 4.42% of the total shares.
Tang Capital Management, LLC holds 2.50M shares, accounting for 4.03% of the total shares.
Pfizer Inc holds 7.03M shares, accounting for 11.34% of the total shares.
GordonMD Global Investments LP holds 3.83M shares, accounting for 6.18% of the total shares.
Laurion Capital Management LP holds 3.63M shares, accounting for 5.85% of the total shares.
Bayer World Investments BV holds 2.74M shares, accounting for 4.42% of the total shares.
Tang Capital Management, LLC holds 2.50M shares, accounting for 4.03% of the total shares.
What are the top three shareholder types of Pyxis Oncology Inc?
The top three shareholder types of Pyxis Oncology Inc are:
Pfizer Inc
GordonMD Global Investments LP
Laurion Capital Management LP
Pfizer Inc
GordonMD Global Investments LP
Laurion Capital Management LP
How many institutions hold shares of Pyxis Oncology Inc (PYXS)?
As of 2025Q3, 203 institutions hold shares of Pyxis Oncology Inc, with a combined market value of approximately 20.78M, accounting for 33.38% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -29.10%.
What is the biggest source of revenue for Pyxis Oncology Inc?
In --, the -- business generated the highest revenue for Pyxis Oncology Inc, amounting to -- and accounting for --% of total revenue.
